Solanezumab for Preclinical Alzheimer's: Phase 3 Data : vima

Solanezumab, a monoclonal antibody that binds to the monomeric or soluble form of amyloid-beta, is no better than placebo in slowing the progression of preclinical Alzheimer's, results of a phase 3 trial show.

Related Keywords

Massachusetts , United States , Bristol Myers Squibb , Reisa Sperling , Claire Sexton , Eli Lilly , Harvard Medical School , Foundation For Neurologic Diseases , Davis Alzheimer Prevention Program , Alzheimer Association , Alzheimer Research , Albert Einstein College Of Medicine , Alzheimer Association International Conference , Genentech , National Institute On , Yugilbar Foundation , Massachusetts General Hospital , Medscape Medical , Anti Amyloid Treatment , Asymptomatic Alzheimer , Association International Conference , New England Journal , Amyloid Accumulation , Preclinical Alzheimer Cognitive Composite , Cognitive Function Index , Disease Cooperative Study Activities , Daily Living Prevention Questionnaire , Medscape Medical News , National Institute , Accelerating Medicines Partnership Through , National Institutes , Avid Radiopharmaceuticals , Albert Einstein College , Presented July ,